Sanofi in talks with Advent to sell its European generics arm for €1.9bn

 
Courtney Goldsmith
Follow Courtney
GABON-PHARMACEUTICAL-FACTORY
Sanofi is flogging its European generics arm (Source: Getty)

France's top drugmaker, Sanofi, has entered exclusive talks with private equity firm Advent International over the sale of its European generics business for €1.9bn (£1.6bn).

The global investor has made a binding and fully financed offer for Zentiva, and Sanofi said the deal is expected to close by the end of 2018.

"Following a comprehensive review of strategic options for our generic unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success,” said Olivier Brandicourt, Sanofi's chief executive.

Read more: French pharma giant Sanofi agrees to buy US biotech Bioverativ for $11.6bn

Tom Allen, co-head of Advent's European healthcare team, and Cedric Chateau, head of Advent in France, said Zentiva offers a great platform full of talented people "who we can invest behind to build a new, independent, European generics leader".

In recent months, Sanofi has been hoovering up biotech firms, including the maker of a rare blood disease treatment, Ablynx, for €3.9bn and ​US biotech Bioverativ for $11.6bn (£8.1bn)

Knut Slatten, the vice president and lead analyst for Sanofi at Moody's, said:

The €1.9bn disposal of Zentiva is credit positive and will contribute to a lessening of Sanofi’s increased net debt burden following its acquisition of Bioverativ and Ablynx for more than €13 billion earlier in the year.

This week, Sanofi also sold some brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturng unit for €158m.

A sale of the unit has been on the cards since October, after Sanofi spent more than a year carving out the generics division into a stand-alone company.

Read more: Biotech M&A heats up as Sanofi buys Ablynx for €3.9bn

Related articles